OTX-TKI

Phase 3

Ocular Therapeutix, Inc. (OCUL)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

OCULPhase 3$2.2B

OTX-TKI Phase 3 Est. Readout

OTX-TKI• Neovascular Age-related Macular Degeneration825

Jan 2027~Confirmed

CT.gov

00%

Competitive Landscape

1 competitor in Neovascular Age-related Macular Degeneration

CLSDCLS-AX

Phase 2

View Full Landscape

Drug Information

Target Indication

Neovascular Age-related Macular Degeneration

Clinical Trial

NCT06495918

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

OCUL

Ocular Therapeutix, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Ophthalmic InsertPhase 3

Open Angle Glaucoma and Ocular Hypertension

Punctum PlugPhase 3

Post Ocular Surgical Inflammation and Pain

OTX-TKI (axitinib implant)Phase 3

Neovascular Age-Related Macular Degeneration

Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24Phase 3

Non-Proliferative Diabetic Retinopathy

Dextenza Ophthalmic InsertPhase 3

Cataract

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts